357 related articles for article (PubMed ID: 28336784)
1. Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis.
Sucksdorff M; Rissanen E; Tuisku J; Nuutinen S; Paavilainen T; Rokka J; Rinne J; Airas L
J Nucl Med; 2017 Oct; 58(10):1646-1651. PubMed ID: 28336784
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹C-PK11195.
Rissanen E; Tuisku J; Rokka J; Paavilainen T; Parkkola R; Rinne JO; Airas L
J Nucl Med; 2014 Jun; 55(6):939-44. PubMed ID: 24711650
[TBL] [Abstract][Full Text] [Related]
3. In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis.
Airas L; Dickens AM; Elo P; Marjamäki P; Johansson J; Eskola O; Jones PA; Trigg W; Solin O; Haaparanta-Solin M; Anthony DC; Rinne J
J Nucl Med; 2015 Feb; 56(2):305-10. PubMed ID: 25572093
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab treatment reduces microglial activation in the white matter of the MS brain.
Sucksdorff M; Tuisku J; Matilainen M; Vuorimaa A; Smith S; Keitilä J; Rokka J; Parkkola R; Nylund M; Rinne J; Rissanen E; Airas L
Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e574. PubMed ID: 31355310
[TBL] [Abstract][Full Text] [Related]
5. (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas.
Park E; Gallezot JD; Delgadillo A; Liu S; Planeta B; Lin SF; O'Connor KC; Lim K; Lee JY; Chastre A; Chen MK; Seneca N; Leppert D; Huang Y; Carson RE; Pelletier D
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1081-92. PubMed ID: 25833352
[TBL] [Abstract][Full Text] [Related]
6.
Datta G; Colasanti A; Kalk N; Owen D; Scott G; Rabiner EA; Gunn RN; Lingford-Hughes A; Malik O; Ciccarelli O; Nicholas R; Nei L; Battaglini M; De Stefano N; Matthews PM
J Nucl Med; 2017 Sep; 58(9):1477-1482. PubMed ID: 28302760
[TBL] [Abstract][Full Text] [Related]
7. Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome.
Giannetti P; Politis M; Su P; Turkheimer FE; Malik O; Keihaninejad S; Wu K; Waldman A; Reynolds R; Nicholas R; Piccini P
Brain; 2015 Jan; 138(Pt 1):110-9. PubMed ID: 25416179
[TBL] [Abstract][Full Text] [Related]
8. Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging.
Bezukladova S; Tuisku J; Matilainen M; Vuorimaa A; Nylund M; Smith S; Sucksdorff M; Mohammadian M; Saunavaara V; Laaksonen S; Rokka J; Rinne JO; Rissanen E; Airas L
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32123046
[TBL] [Abstract][Full Text] [Related]
9. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.
Sucksdorff M; Matilainen M; Tuisku J; Polvinen E; Vuorimaa A; Rokka J; Nylund M; Rissanen E; Airas L
Brain; 2020 Dec; 143(11):3318-3330. PubMed ID: 33006604
[TBL] [Abstract][Full Text] [Related]
10. Neuroinflammatory component of gray matter pathology in multiple sclerosis.
Herranz E; Giannì C; Louapre C; Treaba CA; Govindarajan ST; Ouellette R; Loggia ML; Sloane JA; Madigan N; Izquierdo-Garcia D; Ward N; Mangeat G; Granberg T; Klawiter EC; Catana C; Hooker JM; Taylor N; Ionete C; Kinkel RP; Mainero C
Ann Neurol; 2016 Nov; 80(5):776-790. PubMed ID: 27686563
[TBL] [Abstract][Full Text] [Related]
11. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
[TBL] [Abstract][Full Text] [Related]
12. A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis.
Nutma E; Stephenson JA; Gorter RP; de Bruin J; Boucherie DM; Donat CK; Breur M; van der Valk P; Matthews PM; Owen DR; Amor S
Brain; 2019 Nov; 142(11):3440-3455. PubMed ID: 31578541
[TBL] [Abstract][Full Text] [Related]
13. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.
Datta G; Colasanti A; Rabiner EA; Gunn RN; Malik O; Ciccarelli O; Nicholas R; Van Vlierberghe E; Van Hecke W; Searle G; Santos-Ribeiro A; Matthews PM
Brain; 2017 Nov; 140(11):2927-2938. PubMed ID: 29053775
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod treatment reverses signs of diffuse white matter damage in multiple sclerosis: A pilot study.
Saraste M; Bezukladova S; Sucksdorff M; Saunavaara V; Rissanen E; Matilainen M; Airas L
Mult Scler Relat Disord; 2021 Feb; 48():102690. PubMed ID: 33352357
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis.
Oommen VV; Tauhid S; Healy BC; Chua AS; Malik MT; Diaz-Cruz C; Dupuy SL; Weiner HL; Chitnis T; Bakshi R
J Neuroimaging; 2016; 26(2):184-7. PubMed ID: 26445919
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis.
Lehto J; Nylund M; Matilainen M; Sucksdorff M; Vuorimaa A; Rajander J; Wahlroos S; Hariri P; Airas L
Eur J Neurol; 2023 Aug; 30(8):2365-2375. PubMed ID: 37154404
[TBL] [Abstract][Full Text] [Related]
17. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study.
Versijpt J; Debruyne JC; Van Laere KJ; De Vos F; Keppens J; Strijckmans K; Achten E; Slegers G; Dierckx RA; Korf J; De Reuck JL
Mult Scler; 2005 Apr; 11(2):127-34. PubMed ID: 15794383
[TBL] [Abstract][Full Text] [Related]
18. In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18)F-PBR111 PET.
Colasanti A; Guo Q; Muhlert N; Giannetti P; Onega M; Newbould RD; Ciccarelli O; Rison S; Thomas C; Nicholas R; Muraro PA; Malik O; Owen DR; Piccini P; Gunn RN; Rabiner EA; Matthews PM
J Nucl Med; 2014 Jul; 55(7):1112-8. PubMed ID: 24904112
[TBL] [Abstract][Full Text] [Related]
19. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.
Banati RB; Newcombe J; Gunn RN; Cagnin A; Turkheimer F; Heppner F; Price G; Wegner F; Giovannoni G; Miller DH; Perkin GD; Smith T; Hewson AK; Bydder G; Kreutzberg GW; Jones T; Cuzner ML; Myers R
Brain; 2000 Nov; 123 ( Pt 11)():2321-37. PubMed ID: 11050032
[TBL] [Abstract][Full Text] [Related]
20. Activated microglia do not increase 18 kDa translocator protein (TSPO) expression in the multiple sclerosis brain.
Nutma E; Gebro E; Marzin MC; van der Valk P; Matthews PM; Owen DR; Amor S
Glia; 2021 Oct; 69(10):2447-2458. PubMed ID: 34145928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
